Escina

FLEBOSTASIN RETARD 50 mg CÁPSULAS DURAS DE LIBERACIÓN PROLONGADA

50 mg cápsula dura de liberación prolongadaSpainMarketedAuthorised 29 Feb 1996

In other countries

The same active substances on other registers, the same brand first.

EdevexinItaly · Compressa rivestita con film · Istituto Biochimico Italiano Giovanni Lorenzini S.P.A.Same substance
ReparilexinItaly · Compressa rivestita · Cooper Consumer Health B.V.Same substance
Reparil 20MG TabSaudi Arabia · Rottapharm|Madaus GroupSame substance
Reparil Amp 5MGSaudi Arabia · Rottapharm|Madaus GroupSame substance

Packs

Pack	Code	Status
FLEBOSTASIN RETARD 50 mg CÁPSULAS DURAS DE LIBERACIÓN PROLONGADA, 60 cápsulas	694711

Documents

The official texts, at the regulator.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Escina

FLEBOSTASIN RETARD 50 mg CÁPSULAS DURAS DE LIBERACIÓN PROLONGADA

50 mg cápsula dura de liberación prolongadaSpainMarketedAuthorised 29 Feb 1996

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Packs

Pack	Code	Status
FLEBOSTASIN RETARD 50 mg CÁPSULAS DURAS DE LIBERACIÓN PROLONGADA, 60 cápsulas	694711

Documents

The official texts, at the regulator.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Summary of product characteristicsAEMPS

Package leafletAEMPS

Register entryAEMPS

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Escina
Strength: 50 mg
Dosage form: cápsula dura de liberación prolongada
Route: vía oral
Register: Spain (AEMPS)
Status: Marketed
Status in the register: Autorizado, comercializado
Authorised: 29 Feb 1996
Registration: 60194
Marketing authorisation holder: Glenwood Gmbh Pharmazeutische Erzeugnisse
Procedure: National, MRP or DCP
Supply: Medicamento Sujeto A Prescripción Médica